Company profile: AnaptysBio
1.1 - Company Overview
Company description
- Provider of antibody therapeutics developed via somatic hypermutation, including Imsidolimab (IgG4 anti-IL-36 receptor) for generalized pustular psoriasis; Rosnilimab (PD-1 agonist) for rheumatoid arthritis and ulcerative colitis; ANB032 (BTLA agonist) for atopic dermatitis; ANB033 (anti-CD122 antagonist) for autoimmune and inflammatory diseases; and ANB101 (BDCA2 modulator) targeting plasmacytoid dendritic cells to inhibit interferon secretion.
Products and services
- ANB032: A BTLA agonist antibody aimed at treating atopic dermatitis by inhibiting activated T cell proliferation and modulating dendritic cell function
- ANB033: An anti-CD122 antagonist antibody targeting the shared beta subunit of IL-15 and IL-2 receptors for autoimmune and inflammatory diseases
- ANB101: A BDCA2 modulator antibody targeting plasmacytoid dendritic cells to inhibit interferon secretion in autoimmune and inflammatory diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AnaptysBio
Prokarium
HQ: United Kingdom
Website
- Description: Provider of microbial immunotherapy and synthetic biology–based immuno-oncology therapeutics. Offers ZH9, an investigational intravesical monotherapy to prevent recurrences in non‑muscle invasive bladder cancer; the Living Cures Platform for delivering therapeutic cargo and nucleic acids; IO Prime, an oral immune fitness agent; and Entervax, a bivalent oral enteric fever vaccine in phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prokarium company profile →
Celyad Oncology
HQ: Belgium
Website
- Description: Provider of cell therapy treatments for severe diseases in immuno-oncology and cardiology, developing CAR T-cell technologies and medical devices. Offers a multispecific CAR approach targeting NKG2D ligands plus another target to address resistance and immune escape, and shRNA multiplexing for non-gene edited CAR T cells. Pipeline includes CAR-T NKR-2, C-Cure, and CYAD-01/02/03.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celyad Oncology company profile →
Selexis
HQ: Switzerland
Website
- Description: Provider of proprietary technology and highly specialized expertise for mammalian (suspension-adapted CHO-K1) cell line generation, helping translate scientific innovation into life-saving medicines for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selexis company profile →
Obsidian Therapeutics
HQ: United States
Website
- Description: Provider of next-generation cell and gene therapies to extend adoptive immunotherapy, offering the cytoDRiVE platform that controls protein function using drug-responsive domains and FDA-approved small molecules, and OBX-115, a TIL cell therapy engineered to produce membrane-bound IL15 to eliminate co-administered high-dose IL2 in advanced or metastatic melanoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Obsidian Therapeutics company profile →
Vical
HQ: United States
Website
- Description: Provider of biopharmaceutical product research and development based on its patented DNA delivery technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AnaptysBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AnaptysBio
2.2 - Growth funds investing in similar companies to AnaptysBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AnaptysBio
4.2 - Public trading comparable groups for AnaptysBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →